GORE® VIATORR® TIPS Endoprosthesis Receives CE Mark, Enhancing Portal Hypertension Treatment Options

GORE® VIATORR® TIPS Endoprosthesis Expands Options for Portal Hypertension Treatment

W. L. Gore & Associates Medical Products has recently secured CE mark approval for its innovative GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion, now available in a diameter range of 6-10 mm. This development significantly enhances the therapeutic options available to physicians treating portal hypertension, a serious condition resulting from increased blood pressure in the portal venous system. Previously, the device was limited to an 8-10 mm diameter, but the addition of smaller sizes allows for more personalized treatment strategies tailored to individual patient anatomy and needs.

The expanded diameter options enable clinicians to better manage the portal pressure gradient, a critical factor in reducing complications associated with portal hypertension, such as hepatic encephalopathy and cardiac overload. Professor Filippo Schepis from the University Hospital of Modena underscores the importance of optimizing shunt diameter in improving patient outcomes. With over 25 years of clinical performance history and more than 500 publications backing its reliability, the GORE® VIATORR® device stands out as the only covered TIPS device with such extensive documentation supporting its efficacy in a clinical setting.

The construction of the GORE® VIATORR® Endoprosthesis features Gore's proprietary ePTFE graft lining, specifically designed to resist bile and mucin permeation—common factors that lead to patency loss in transjugular intrahepatic portosystemic shunts (TIPS). The introduction of this new device with expanded diameter options is expected to transform clinical practice, offering healthcare providers a meaningful tool in the fight against portal hypertension. By allowing for more precise, customized interventions, this advancement promises to lead to improved patient outcomes and a reduction in the potential for complications associated with the condition.

In addition to its historical reliability, the GORE® VIATORR® TIPS Endoprosthesis exemplifies a commitment to innovation in the medical device industry. As the healthcare landscape continues to evolve, such advancements are crucial for addressing the complexities of patient care and improving the overall quality of life for those affected by chronic conditions like portal hypertension.

Overall, the launch of the new GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion marks a significant milestone in the treatment of portal hypertension, showcasing how targeted innovations can enhance clinical efficacy and patient safety.